Overview

Methylnaltrexone vs Naloxegol in the Treatment of Opioid-Induced Constipation

Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to compare the efficacy of subcutaneous versus oral mu-opioid receptor antagonist therapy in opioid induced constipation that is refractory to other bowel regimens.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of Missouri-Columbia
Treatments:
Analgesics, Opioid
Bromides
Methylnaltrexone
Naloxegol
Naltrexone
Criteria
Inclusion Criteria:

- Complaint of opioid-induced constipation refractory to other therapy (enemas,
laxatives, stool softeners)

- Ageā‰„18y/o

- Not pregnant or lactating (negative urinary pregnancy test)

- No contraindication to Methylnaltrexone or Naloxegol

Exclusion Criteria:

- Age<18y/o

- Pregnancy or lactation

- Contraindication to Methylnaltrexone or Naloxegol

- Assigned NPO

- Small bowel obstruction